![[Logo-reDesign]-Orphinic](http://orphinic.com/wp-content/uploads/elementor/thumbs/Logo-reDesign-Orphinic-1-o418776nov3gx5154b1hwxwiykwpn6l9hu8h5y1eus.png "[Logo-reDesign]-Orphinic"){kind=logo}
About us
ORPHINIC is an orphan drug development specialist.
We search for the best in class projects worldwide that potentially deliver life changing treatments. We work together with the scientists and lead the clinical research, regulatory and transactional matters.
We select the projects that have high market potential and relatively low risk of failure. We want to make sure that, if successful, the solution will significantly improve patient’s life.
The strategy of Orphinic is to acquire post-preclinical phase molecules ready to enter phase 1 or phase 2. (has to be ready within max. 12 months).
The current portfolio includes Scleroderma treatment in pre-Phase 2.
Several other molecules are currently being verified and negotiated.
The portfolio will consist of more than 10 different projects.
Why Orphinic
It represents a unique company in the European Economic Community and one among the few similar existing in the world;
The team has an in-house know how of best in class clinical research done in cost effective and time efficient manner;
Therapeutic Innovation
The pharmaceutical industry suffers from a strong disagreement between the development of scientific innovation and the limited availability of resources.
There are over 7,000 rare diseases affecting 7% of the population and only 340 of these disorders currently have treatment.
The Orphinic’s strategic advantage is to perform clinical tests mainly in Eastern Europe. This guarantees a much faster process, with good quality and at a lower cost, thus creating the best value for our investors. The company guarantees costs reduction by 20% and timeline reduction by 30% compared to the rest of Europe or the USA also thanks to a proprietary software solution. After the Phase 1, performed internally, follows a Phase 2 outsourced to local or regional CRO taking advantage of an international medical experience. Regulation takes place internally too.
Finally, Orphinic collaborates with the major pharmaceutical industries to enter the market.
Pipeline and research
10+ projects in the pipeline currently under negotiations.
Team
Adam Kruszewski – CEO – MD, MBA – entrepreneur, investor and executive with over 20y experience (pharma, health care sector, PE, VC) – CEE countries and in the US. Built and managed international operations up to 2,000 people, 100M $ revenue and 16 countries. Led successful turn-a rounds (KCR, Luxmed, Medicover, Medycyna Rodzinna, phase2micro), grew up, built, managed and sold successfully own international business. Health care expert advising governments, being member of Boards of Directors in big companies, setting up influential health care think tank (CEE HPN).
Filippo Surace – CHAIRMAN – MD, MHA, EMPHA – Founder and President of a pharma/medical devices incubator Cube-Lab, aggregating 50+ R&D companies from Academy with 250+ patents/products. CEO of a number of Accademy Spin off in the pharma field with extensive C-level experience. VC experience throughout funding to exits. Professor of biotechnology at Temple University (USA). Key note speaker in Silicon Valley. Won multiple innovation awards (China Awards, Le Fondi Awards – Stock Exchange Market London, Forbes, Milano Finanza, +N).
Wojciech Tomikowski – CFO – MSc, former country CEO for a global consumer health company (Novartis Consumer Health/ Gerber) where he worked in South America, China, Russia and Europe, also involved in M&A and business development activities worldwide.
M&A advisory boutique owner, Partner in PE/VC investment company. Experienced in M&A transactions of all types, including successful exits, restructurings, licence and cooperation deals.
Grażyna Szymańska – Ph.D. – Senior executive and angel investor with over 20 years’ experience in forming, building and operating new science-based ventures (Creative BioMolecules, Curis, ToleRx, TEI Biosciences and ViThera Pharmaceuticals). She has actively collaborated and advised university technology transfer offices and innovation initiatives at Harvard, Harvard Business School, BU’s School of Management Strategy & Innovation, and MIT. Member of scientific advisory board for the Center for Integration of Medicine and Innovative Technology in Boston, Astia- global incubator for guiding and launching women owned businesses.
Our values
